Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

5(83.3%)

Phase 2

1(16.7%)

6Total

Phase 1(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05189093Phase 1Completed

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Role: lead

NCT06708663Phase 1Recruiting

HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

Role: lead

NCT04886271Phase 2Completed

Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors

Role: lead

NCT06703255Phase 1Recruiting

A Phase 2 Study of HX301 in Patients with High-grade Giloma

Role: lead

NCT05731752Phase 1Active Not Recruiting

Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

Role: lead

NCT05731934Phase 1Completed

The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors

Role: lead

All 6 trials loaded